| Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study D Gouglas, TT Le, K Henderson, A Kaloudis, T Danielsen, ... The Lancet Global Health 6 (12), e1386-e1396, 2018 | 252* | 2018 |
| Antibiotic research and development: business as usual? S Harbarth, U Theuretzbacher, J Hackett, Drive-AB Consortium, ... Journal of Antimicrobial Chemotherapy 70 (6), 1604-1607, 2015 | 114 | 2015 |
| Multi-criteria decision analysis to support healthcare decisions K Marsh, M Goetghebeur, P Thokala, R Baltussen Springer 10, 978-3, 2017 | 109 | 2017 |
| CEPI: Driving Progress Towards Epidemic Preparedness And Response D Gouglas, M Christodoulou, S Plotkin, R Hatchett Epidemiologic Reviews, 2019 | 100 | 2019 |
| New vaccines against epidemic infectious diseases JA Røttingen, D Gouglas, M Feinberg, S Plotkin, KV Raghavan, A Witty, ... New England journal of medicine 376 (7), 610-613, 2017 | 92 | 2017 |
| Neglected disease research & development: a five year review M Moran, J Guzman, K Henderson, R Liyanage, L Wu, E Chin, ... http://www.policycuresresearch.org/downloads/GF2012_Report.pdf, 2012 | 49 | 2012 |
| A review of Lassa fever vaccine candidates K Salami, D Gouglas, C Schmaljohn, M Saville, N Tornieporth Current Opinion in Virology 37, 105-111, 2019 | 42 | 2019 |
| Designing Pull Funding For A COVID-19 Vaccine CM Snyder, K Hoyt, D Gouglas, T Johnston, J Robinson Health Affairs, 2020 | 38 | 2020 |
| Neglected Disease Research and Development: Is Innovation Under Threat? M Moran, J Guzman, L Abela-Oversteegen, R Liyanage, B Omune, L Wu, ... http://policycures.org/downloads/g-finder_2011.pdf, 2011 | 26 | 2011 |
| Gavi’s policy steers country ownership and self-financing of immunization K Henderson, D Gouglas, L Craw Vaccine 34 (37), 4354-4359, 2016 | 13 | 2016 |
| Prioritizing investments in new vaccines against epidemic infectious diseases: A multi‐criteria decision analysis D Gouglas, K Marsh Journal of Multi-Criteria Decision Analysis, 1-11, 2019 | 12 | 2019 |
| The 100 Days Mission—2022 Global Pandemic Preparedness Summit D Gouglas, M Christodoulou, R Hatchett Emerging Infectious Diseases 29 (3), 2023 | 10 | 2023 |
| R&D for emerging infectious diseases of epidemic potential: sharing risks and benefits through a new coalition U Gopinathan, E Peacocke, D Gouglas, T Ottersen, JA Røttingen Infectious Diseases in the New Millennium: Legal and Ethical Challenges, 137-165, 2020 | 8 | 2020 |
| Setting strategic objectives for the coalition for epidemic preparedness innovations: An exploratory decision analysis process D Gouglas, K Hoyt, E Peacocke, A Kaloudis, T Ottersen, JA Røttingen INFORMS Journal on Applied Analytics 49 (6), 430-446, 2019 | 8 | 2019 |
| Prioritizing investments in rapid response vaccine technologies for emerging infections: A portfolio decision analysis D Gouglas, K Marsh PLoS ONE 16 (2), e0246235, 2021 | 7 | 2021 |
| An optimal mechanism to fund the development of vaccines against emerging epidemics CM Snyder, K Hoyt, D Gouglas Journal of Health Economics 91, 102795, 2023 | 3 | 2023 |
| Vaccine-based mitigation of the 2014 Ebola Viral Disease (EVD) epidemic: Gap analysis and proposal for Norwegian initiatives G Norheim, F Oftung, S Watle, BS Wiklund, D Gouglas, KM Schoultz, ... Report to the Norwegian Ministry of Health, Norwegian Institute of Public …, 2014 | 3 | 2014 |
| Evaluation of the GAVI Alliance Co-financing Policy D Gouglas, K Henderson, J Plahte, C Årdal, JA Røttingen Draft Report commissioned by the GAVI Alliance. Oslo: Norwegian Institute of …, 2014 | 3 | 2014 |
| The role of MCDA in health research priority setting RF Viergever, D Gouglas, N Tromp Multi-criteria decision analysis to support healthcare decisions, 217-237, 2017 | 2 | 2017 |
| Prioritizing investments in new vaccines against epidemic infectious diseases: a multi-criteria decision analysis D Gouglas, K Marsh VALUE IN HEALTH 21, S240-S240, 2018 | 1 | 2018 |
